Literature DB >> 31472958

Silencing of TRIM10 alleviates apoptosis in cellular model of Parkinson's disease.

Qiong Huang1, Xiaoqi Zhu2, Min Xu3.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neuron loss, inflammation and oxidative stress injury in the substantia nigra pars compacta (SNpc). Tripartite motif 10 (TRIM10) belongs to the TRIM family of proteins and has been implicated to play a role in in PD, although supporting evidence has yet to be established. 1-methyl-4-phenylpyridinium (MPP+), the metabolite of MPTP (Mitochondrial parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine), is often used to generate a cellular model of PD. In this study, we found that MPP + inhibited cell proliferation and induced TRIM10 expression. Knockdown of TRIM10 alleviated cell apoptosis and ROS generation induced by MPP+. Further, MPP + decreased the expression of dual specificity phosphatase 6 (DUSP6) and this effect was reversed by TRIM10 knockdown. Moreover, DUSP6 alleviated cell apoptosis and ROS generation induced by TRIM10. Of note, TRIM10 suppressed DUSP6 by promoting DUSP6 ubiquitination. In conclusion, silencing of TRIM10 reduced cell apoptosis and ROS levels in a cellular model of PD, suggesting a potential role of TRIM10 in PD treatment.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  DUSP6; MPP+; PD; TRIM10

Mesh:

Substances:

Year:  2019        PMID: 31472958     DOI: 10.1016/j.bbrc.2019.08.041

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway.

Authors:  Hui Yang; Xiao-Xiao Wang; Chun-Yu Zhou; Xue Xiao; Cui Tian; Hui-Hua Li; Chun-Lin Yin; Hong-Xia Wang
Journal:  J Cell Mol Med       Date:  2020-04-28       Impact factor: 5.310

2.  Zenglv Fumai Granule protects cardiomyocytes against hypoxia/reoxygenation-induced apoptosis via inhibiting TRIM28 expression.

Authors:  Xiao-Hua Zhang; Hong-Yu Zhao; Yu Wang; Lin Di; Xin-Yu Liu; Feng Qian; Shu-Rong Liu
Journal:  Mol Med Rep       Date:  2021-01-05       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.